Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 4 1

Status

Not yet recruiting 4Completed 3Recruiting 2Terminated 1

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other solid neoplasm 3

Conditions

Breast Neoplasms 681Neoplasms 593Carcinoma, Non-Small-Cell Lung 292Colorectal Neoplasms 291Prostatic Neoplasms 284Lung Neoplasms 224Melanoma 161Multiple Myeloma 151Neoplasm Metastasis 145Pancreatic Neoplasms 143Head and Neck Neoplasms 143Ovarian Neoplasms 136Carcinoma, Hepatocellular 126Leukemia, Myeloid, Acute 122Colonic Neoplasms 114Brain Neoplasms 113Squamous Cell Carcinoma of Head and Neck 111Uterine Cervical Neoplasms 109Stomach Neoplasms 104Lymphoma 101Recurrence 100Glioblastoma 96Precursor Cell Lymphoblastic Leukemia-Lymphoma 83Lymphoma, Non-Hodgkin 82Urinary Bladder Neoplasms 78Lymphoma, Follicular 78Hematologic Neoplasms 78Glioma 75Parkinson Disease 4, Autosomal Dominant Lewy Body 73Sarcoma 72

Interventions

sacituzumab govitecan 1bintrafusp alfa protein, human 1Tomography, X-Ray Computed 1Nivolumab 1Ipilimumab 1Electrocardiography 1Echocardiography 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Metastatic Solid Tumors × 1 year × Clear all
NCT04457778 2026-05-04

First in Human Study of M6223

EMD Serono

Phase 1 Completed
58 enrolled 38 charts
Other solid neoplasm

Metastatic Solid Tumors

NCT03388632 2025-12-18

Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
31 enrolled 20 charts
Other solid neoplasm

Metastatic Solid Tumors

NCT04319198 2025-09-30

Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziy

Gilead Sciences

Phase 4 Completed
25 enrolled 15 charts
Other solid neoplasm

Metastatic Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡